GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

GSK (GSK) plc announced the authorization of Blenrep by the Medicines and Healthcare products Regulatory Agency. “In the UK, Blenrep is approved for the treatment of adults with multiple myeloma ...

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their ...

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc, Pfizer Inc. and other drugmakers to overturn a judge who allowed more than 80,000 lawsuits to proceed to ...

Bearish flow noted in GSK (GSK) Pharma with 3,615 puts trading, or 1.6x expected. Most active are May-25 30 puts and Aug-25 35 puts, with total volume in those strikes near 2,700 contracts.

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

You can reach Andrew on Signal at drewqjoseph.45. GSK’s blood cancer drug Blenrep won regulatory approval in the U.K. on Thursday, marking the medicine’s return to the market after it was ...

GSK received approval from U.K.'s medicines regulatory body to bring its blood-cancer blockbuster candidate Blenrep back to the market, enabling the British pharma giant to expand its oncology ...

(Alliance News) - GSK PLC on Thursday said it has received authorisation from the UK Medicines & Healthcare products Regulatory Agency for Blenrep combinations in the treatment of adults with ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. GSK has three segments: Specialty Medicines (HIV, Oncology, Immunology/Respiratory and Other), Vaccines ...

(Alliance News) - GSK PLC on Wednesday said it received two significant endorsements from a US advisory panel, bolstering its respiratory syncytial virus and meningitis vaccine portfolios.